DE60040397D1 - Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung - Google Patents
Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendungInfo
- Publication number
- DE60040397D1 DE60040397D1 DE60040397T DE60040397T DE60040397D1 DE 60040397 D1 DE60040397 D1 DE 60040397D1 DE 60040397 T DE60040397 T DE 60040397T DE 60040397 T DE60040397 T DE 60040397T DE 60040397 D1 DE60040397 D1 DE 60040397D1
- Authority
- DE
- Germany
- Prior art keywords
- substituted alpha
- hydroxy acids
- alpha hydroxy
- caspase inhibitors
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102000011727 Caspases Human genes 0.000 title abstract 2
- 108010076667 Caspases Proteins 0.000 title abstract 2
- 229940061720 alpha hydroxy acid Drugs 0.000 title abstract 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15107799P | 1999-08-27 | 1999-08-27 | |
US15837399P | 1999-10-12 | 1999-10-12 | |
PCT/US2000/023566 WO2001016093A1 (en) | 1999-08-27 | 2000-08-28 | SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60040397D1 true DE60040397D1 (de) | 2008-11-13 |
Family
ID=26848309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60040397T Expired - Fee Related DE60040397D1 (de) | 1999-08-27 | 2000-08-28 | Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung |
Country Status (15)
Country | Link |
---|---|
US (1) | US6495522B1 (de) |
EP (1) | EP1212295B1 (de) |
JP (1) | JP2003508379A (de) |
KR (1) | KR20020033777A (de) |
CN (1) | CN1235875C (de) |
AT (1) | ATE409688T1 (de) |
AU (1) | AU775291B2 (de) |
BR (1) | BR0013666A (de) |
CA (1) | CA2383002A1 (de) |
DE (1) | DE60040397D1 (de) |
EA (1) | EA200200301A1 (de) |
IL (1) | IL148426A0 (de) |
MX (1) | MXPA02002038A (de) |
NO (1) | NO20020938L (de) |
WO (1) | WO2001016093A1 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184210B1 (en) * | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
AU5116099A (en) * | 1998-07-21 | 2000-02-14 | Sui Xiong Cai | Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof |
DE60030097T2 (de) * | 1999-03-16 | 2007-03-08 | Cytovia, Inc., San Diego | Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung |
MXPA01010127A (es) * | 1999-04-09 | 2002-08-20 | Cytovia Inc | Inhibidores de la caspasa y el uso de los mismos. |
CN1994298A (zh) * | 2000-03-29 | 2007-07-11 | 沃泰克斯药物股份有限公司 | 氨基甲酸酯天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途 |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
EP1373515A2 (de) * | 2001-03-29 | 2004-01-02 | Nsgene A/S | Mittel zur hemmung der proteolyse von parkin |
US6777443B2 (en) * | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
US7351702B2 (en) * | 2001-05-23 | 2008-04-01 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
WO2003008373A1 (de) * | 2001-07-19 | 2003-01-30 | Merck Patent Gmbh | Tyrosinhydrazide |
EP1485107A1 (de) | 2002-02-11 | 2004-12-15 | Vertex Pharmaceuticals Incorporated | Phospholipide als caspase-hemmer-prodrugs |
EP1494700A2 (de) * | 2002-04-05 | 2005-01-12 | Cytovia, Inc. | Caspase-hemmer zur behandlung von erkrankungen und zuständen, die durch kontakt mit radionucliden, biologischen mitteln oder chemischen mitteln verursacht wurden |
EP1499898A2 (de) * | 2002-04-19 | 2005-01-26 | Vertex Pharmaceuticals Incorporated | Regulierung von tnf-alpha |
CA2524882A1 (en) * | 2003-05-06 | 2004-11-25 | Cytovia, Inc. | Protease inhibitors for coronaviruses and sars-cov and the use thereof |
CA2557631A1 (en) * | 2004-02-18 | 2005-09-01 | Georgia Tech Research Corporation | Propenoyl hydrazides |
KR101135765B1 (ko) | 2004-03-12 | 2012-04-23 | 버텍스 파마슈티칼스 인코포레이티드 | 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체 |
JP4848367B2 (ja) | 2004-05-15 | 2011-12-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Iceインヒビターを使用した発作の処置 |
EP2295054A1 (de) | 2004-05-27 | 2011-03-16 | Vertex Pharmaceuticals Incorporated | Ice-hemmer zur Behandlung von autoinflammatorischen Erkrankungen |
WO2009076598A1 (en) | 2007-12-12 | 2009-06-18 | Children's Hospital & Research Center At Oakland | Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer |
US8497307B2 (en) * | 2008-09-11 | 2013-07-30 | The Regents Of The University Of Michigan | Aryl guanidine F1F0-ATPase inhibitors and related methods |
HUP1000243A2 (en) | 2010-05-06 | 2012-01-30 | Avidin Kft | 8-hidroxy-quinoline derivatives |
US20140309172A1 (en) | 2010-11-05 | 2014-10-16 | Dagmar Ringe | Ice inhibiting compounds and uses thereof |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
KR102310615B1 (ko) * | 2013-11-21 | 2021-10-08 | 알러간, 인코포레이티드 | 페닐카바메이트 유도체로서의 포밀 펩타이드 수용체 조절제 |
CN104803864B (zh) * | 2014-01-29 | 2017-01-11 | 华东师范大学 | β-羟基-α-氨基酸衍生物及其合成方法和应用 |
GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2381023A1 (fr) | 1977-02-18 | 1978-09-15 | Delalande Sa | Nouveaux oligopeptides trifluoromethyles derives de la l-alanine, leur procede de preparation et leur application en therapeutique |
US4518528A (en) | 1983-05-19 | 1985-05-21 | Rasnick David W | α Amino fluoro ketones |
US5221607A (en) | 1989-09-18 | 1993-06-22 | Scios Nova Inc. | Assays and reagents for amyloid deposition |
US5416013A (en) | 1990-04-04 | 1995-05-16 | Sterling Winthrop Inc. | Interleukin 1β protease and interleukin 1β protease inhibitors |
US5252463A (en) | 1990-06-22 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Clipsin, a chymotrypsin-like protease and method of using same |
US5824297A (en) | 1990-06-25 | 1998-10-20 | Oncogene Science, Inc. | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof |
CA2071674C (en) | 1991-06-21 | 2003-08-19 | Kevin T. Chapman | Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme |
HU220098B (hu) | 1991-08-30 | 2001-10-28 | Vertex Pharmaceuticals Incorporated | Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok |
EP0627926B1 (de) | 1992-02-21 | 1998-08-05 | Merck & Co., Inc. (a New Jersey corp.) | Peptidylderivate und inhibitoren des interleukin-1-g(b)-konvertierenden enzyms |
EP0618223A3 (de) | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptide, die Freisetzung vom Interleukin 1-Bêta, nützlich als entzündungshemmende Wirkstoffe. |
CA2122227A1 (en) * | 1993-04-29 | 1994-10-30 | Roland E. Dolle | Peptide analogs as irreversible interleukin-1.beta. protease inhibitors |
US5462939A (en) | 1993-05-07 | 1995-10-31 | Sterling Winthrop Inc. | Peptidic ketones as interleukin-1β-converting enzyme inhibitors |
JPH0789951A (ja) | 1993-06-03 | 1995-04-04 | Sterling Winthrop Inc | インターロイキン−1β転換酵素阻害剤 |
US6087160A (en) | 1993-06-24 | 2000-07-11 | The General Hospital Corporation | Programmed cell death genes and proteins |
US5866545A (en) | 1993-08-13 | 1999-02-02 | Merck & Co., Inc. | Substituted ketone derivatives as inhibitors of interleukin-1β converting enzyme |
US5759548A (en) | 1993-11-30 | 1998-06-02 | Lxr Biotechnology Inc. | Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
US5565430A (en) | 1994-08-02 | 1996-10-15 | Sterling Winthrop Inc. | Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors |
US5744451A (en) | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
US5843904A (en) | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
DE69711845T2 (de) | 1996-09-12 | 2002-10-31 | Idun Pharmaceuticals Inc | Neue tricyclische verbindungen mit ice/ced-3 protease familie-hemmenden eigenschaften |
US5869519A (en) | 1996-12-16 | 1999-02-09 | Idun Pharmaceuticals, Inc. | C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
DE69734718T2 (de) | 1996-09-12 | 2006-08-24 | Idun Pharmaceuticals, Inc., San Diego | Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie |
US6200969B1 (en) | 1996-09-12 | 2001-03-13 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
US5877197A (en) | 1996-12-16 | 1999-03-02 | Karanewsky; Donald S. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US6184244B1 (en) | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
EP0998300A1 (de) | 1997-03-18 | 2000-05-10 | Basf Aktiengesellschaft | Zusammensetzungen zur modulation der empfänglichkeit für corticosteroiden |
JPH111491A (ja) | 1997-04-18 | 1999-01-06 | Takeda Chem Ind Ltd | ペプチド類及びその剤 |
CN1138472C (zh) | 1997-10-10 | 2004-02-18 | 西托维亚公司 | 二肽型编程性细胞死亡抑制剂及其用途 |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
JPH11180891A (ja) | 1997-12-25 | 1999-07-06 | Dai Ichi Seiyaku Co Ltd | 抗細胞死剤 |
JP2002506829A (ja) | 1998-03-16 | 2002-03-05 | サイトビア インコーポレイテッド | ジペプチドのアポトーシスインヒビターおよびそれらの使用 |
KR20010052307A (ko) | 1998-05-05 | 2001-06-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 인터루킨-1β 전환 효소의 숙신아미드 저해제 |
US6197750B1 (en) | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US6201118B1 (en) | 1998-08-19 | 2001-03-13 | Vertex Pharmaceuticals Inc. | Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor |
US6242422B1 (en) | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
CA2353079A1 (en) | 1998-12-02 | 2000-06-08 | Merck Frosst Canada Inc. | Gamma-ketoacid tetrapeptides as inhibitors of caspase-3 |
CA2367862A1 (en) | 1999-03-16 | 2000-09-21 | Merck Frosst Canada & Co. | Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
DE60030097T2 (de) | 1999-03-16 | 2007-03-08 | Cytovia, Inc., San Diego | Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung |
MXPA01010127A (es) | 1999-04-09 | 2002-08-20 | Cytovia Inc | Inhibidores de la caspasa y el uso de los mismos. |
ATE266623T1 (de) | 1999-08-06 | 2004-05-15 | Vertex Pharma | Caspase inhibitoren und deren verwendung |
US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
AR026748A1 (es) | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
CN1994298A (zh) | 2000-03-29 | 2007-07-11 | 沃泰克斯药物股份有限公司 | 氨基甲酸酯天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途 |
WO2001090070A2 (en) | 2000-05-23 | 2001-11-29 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
IL152845A0 (en) | 2000-06-07 | 2003-06-24 | Vertex Pharma | Fused heterocyclic compounds and pharmaceutical compositions containing the same |
-
2000
- 2000-08-28 BR BR0013666-2A patent/BR0013666A/pt not_active Application Discontinuation
- 2000-08-28 AT AT00959495T patent/ATE409688T1/de not_active IP Right Cessation
- 2000-08-28 AU AU70809/00A patent/AU775291B2/en not_active Ceased
- 2000-08-28 DE DE60040397T patent/DE60040397D1/de not_active Expired - Fee Related
- 2000-08-28 MX MXPA02002038A patent/MXPA02002038A/es unknown
- 2000-08-28 WO PCT/US2000/023566 patent/WO2001016093A1/en active IP Right Grant
- 2000-08-28 US US09/649,810 patent/US6495522B1/en not_active Expired - Fee Related
- 2000-08-28 IL IL14842600A patent/IL148426A0/xx unknown
- 2000-08-28 EA EA200200301A patent/EA200200301A1/ru unknown
- 2000-08-28 CA CA002383002A patent/CA2383002A1/en not_active Abandoned
- 2000-08-28 JP JP2001519663A patent/JP2003508379A/ja not_active Withdrawn
- 2000-08-28 KR KR1020027002581A patent/KR20020033777A/ko not_active Application Discontinuation
- 2000-08-28 EP EP00959495A patent/EP1212295B1/de not_active Expired - Lifetime
- 2000-08-28 CN CNB008134464A patent/CN1235875C/zh not_active Expired - Fee Related
-
2002
- 2002-02-26 NO NO20020938A patent/NO20020938L/no unknown
Also Published As
Publication number | Publication date |
---|---|
JP2003508379A (ja) | 2003-03-04 |
EP1212295A1 (de) | 2002-06-12 |
KR20020033777A (ko) | 2002-05-07 |
BR0013666A (pt) | 2002-05-14 |
US6495522B1 (en) | 2002-12-17 |
CA2383002A1 (en) | 2001-03-08 |
NO20020938L (no) | 2002-04-15 |
ATE409688T1 (de) | 2008-10-15 |
NO20020938D0 (no) | 2002-02-26 |
EA200200301A1 (ru) | 2002-08-29 |
CN1235875C (zh) | 2006-01-11 |
AU775291B2 (en) | 2004-07-29 |
IL148426A0 (en) | 2002-09-12 |
MXPA02002038A (es) | 2002-10-31 |
CN1382119A (zh) | 2002-11-27 |
AU7080900A (en) | 2001-03-26 |
EP1212295B1 (de) | 2008-10-01 |
WO2001016093A1 (en) | 2001-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60040397D1 (de) | Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung | |
DE60035037D1 (de) | Caspase inhibitoren und ihre verwendung | |
ATE336480T1 (de) | Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung | |
DE69925268D1 (de) | Dipeptid kaspase inhibitoren und deren verwendung | |
ATE253545T1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
WO2002100826A3 (en) | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs | |
ATE309237T1 (de) | Aromatische heterozyklische verbindungen als antientzündungwirkstoffe | |
DE60036726D1 (de) | Harnstoff derivate als entzündungshemmende mittel | |
BR0207278A (pt) | Derivados de ftalazinona-piperidina como inibidores de pde4 | |
PT939627E (pt) | Pentafluorobenzenossulfonamidas e analogos | |
DE60008574D1 (de) | Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung | |
ATE301122T1 (de) | Kernerweiterte perylenbisimide und ihre verwendung als fluoreszenzfarbstoffe | |
DE60234589D1 (de) | Substituierte 4h-chromene und analoga als aktivatoren von caspasen und induktoren von apoptose, und deren verwendung als antikrebsmittel | |
TR200201168T2 (tr) | CGRP-Antagonistleri-yeni siklopropanlar içeren ilaçlar ve üretim yöntemleri. | |
DE60327811D1 (de) | Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen | |
DE60221505D1 (de) | FAKTOR Xa BENZAMIDIN INHIBITOREN | |
ATE181056T1 (de) | Arylessigsäurederivate und ihre verwendung als fungizide | |
BR0014990A (pt) | Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4 | |
CA2399451A1 (en) | Tyrosine derivatives with anti-leukotriene activity | |
TR200002740T2 (tr) | Piperidinil ve N-Amidinopiperidinil türevleri | |
WO1999065451A3 (en) | Caspases and apoptosis | |
DE60036558D1 (de) | Phthalazinon-derivate als pde 4 hemmer | |
BR0209076A (pt) | Derivados de piperazino e seu uso como inibidor de pde4 | |
DE60107832D1 (en) | Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe | |
BR0010488A (pt) | Tienocicloalqu(en)ilamino-1,3,5-triazinas substituìdas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |